AdAlta (Biotechnology) Overview

  • Founded
  • 2006
Founded
  • Status
  • Public
  • Stock Symbol
  • 1AD
Stock Symbol
  • Share Price
  • $0.06
  • (As of Friday Closing)

AdAlta (Biotechnology) General Information

Description

AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Therapeutic Devices
Stock Exchange
ASX
Primary Office
  • 15/2 Park Drive
  • Bundoora, Victoria 3083
  • Australia
+61 (03) 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AdAlta (Biotechnology) Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.06 $0.06 $0.06 - $0.21 $14.2M 246M 320K

AdAlta (Biotechnology) Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2021 30-Jun-2021 FY 2020 30-Jun-2020 FY 2019 30-Jun-2019
EV 12,927 19,943 8,768 9,888
Revenue 632 412
EBITDA (4,104) (3,931) (4,245)
Net Income (4,196) (4,023) (4,232)
Total Assets 6,799 4,746 6,520
Total Debt 1,268 1,506 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AdAlta (Biotechnology) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AdAlta (Biotechnology)‘s full profile, request access.

Request a free trial

AdAlta (Biotechnology) Patents

AdAlta (Biotechnology) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2973317-A1 Cxcr4 binding molecules Pending 09-Jan-2015 000000000
AU-2019203511-B2 Cxcr4 binding molecules Active 09-Jan-2015 000000000 0
AU-2019203511-A1 Cxcr4 binding molecules Granted 09-Jan-2015 000000000
AU-2017254863-A1 Cxcr4 binding molecules Abandoned 09-Jan-2015 000000000
AU-2016206191-A9 Cxcr4 binding molecules Granted 09-Jan-2015 C07K17/02

AdAlta (Biotechnology) Executive Team (6)

Name Title Board Seat Contact Info
Tim Oldham Chief Executive Officer & Managing Director
Dallas Hartman Chief Operating Officer
Michael Foley Chief Scientific Officer
Cameron Jones Board Member & Company Secretary
Samantha Cobb Founding Chief Executive Officer, Managing Director & Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

AdAlta (Biotechnology) Board Members (7)

Name Representing Role Since
Cameron Jones AdAlta (Biotechnology) Board Member & Company Secretary 000 0000
James Williams Ph.D Yuuwa Capital Board Member 000 0000
John Ballard AdAlta (Biotechnology) Board Member 000 0000
Liddy McCall Yuuwa Capital Board Member 000 0000
Paul MacLeman AdAlta (Biotechnology) Chairman 000 0000
You’re viewing 5 of 7 board members. Get the full list »